Format

Send to

Choose Destination
See comment in PubMed Commons below
Air Med J. 2001 Nov-Dec;20(6):23-5.

Introducing glycoprotein IIb/IIIa inhibitor therapy to air medical practice.

Author information

  • 1LIFE STAR/Hartford Hospital, Hartford, Conn 06102-5037, USA. mfrakes@harthosp.org

Abstract

INTRODUCTION:

In patients with myocardial infarction, platelet aggregation inhibition with glycoprotein IIb/IIIa antagonists helps restore and maintain coronary blood flow when administered alone, with fibrinolytics, or with angioplasty. This article evaluates whether an adequate number of patients transported by an air medical program could benefit from flight team administration of these agents and describes the implementation issues surrounding a treatment protocol.

METHODS:

A retrospective chart review and a discussion of the program's implementation experience

RESULTS:

Seven percent of the patients transported by the air medical program met clinical and electrocardiographic criteria for administration of glycoprotein IIb/IIIa inhibitors. The program identified systemic, budgetary, and logistical issues with protocol implementation that require ongoing consideration.

PMID:
11692135
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk